CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
REVENUES:
Total revenues	$ 387,763	$ 372,845	$ 788,508	$ 746,292
OPERATING EXPENSES:
Cost of sales	77,436	79,019	166,618	161,352
Research and development	185,641	175,582	369,232	359,530
Selling, general and administrative	160,754	153,280	322,912	291,616
Intangible asset amortization and contingent consideration	20,286	10,227	40,051	23,429
Gain on sale of intangible assets	(15,000)	(20,000)	(15,000)	(20,000)
Total operating expenses	429,117	398,108	883,813	815,927
LOSS FROM OPERATIONS	(41,354)	(25,263)	(95,305)	(69,635)
Equity in the loss of BioMarin/Genzyme LLC	(44)	(107)	(229)	(39)
Interest income	5,899	5,569	12,197	10,803
Interest expense	(6,866)	(12,225)	(13,593)	(23,787)
Other income, net	470	2,849	2,078	2,677
LOSS BEFORE INCOME TAXES	(41,895)	(29,177)	(94,852)	(79,981)
Benefit from income taxes	(4,460)	(12,385)	(944)	(19,040)
NET LOSS	$ (37,435)	$ (16,792)	$ (93,908)	$ (60,941)
Earnings Per Share, Basic and Diluted (in dollars per share)	$ (0.21)	$ (0.09)	$ (0.53)	$ (0.35)
Weighted average common shares outstanding, basic (in shares)	179,048	176,873	178,662	176,405
COMPREHENSIVE (LOSS)/INCOME	$ (39,790)	$ 10,624	$ (81,740)	$ (38,523)
Net product revenues
REVENUES:
Total revenues	379,075	367,786	773,558	736,885
Royalty and other revenues
REVENUES:
Total revenues	$ 8,688	$ 5,059	$ 14,950	$ 9,407